Details of the Drug Pharmacogenomic Perturbation Atlas

Vindesine Drug Info

DAVA; Vindesin; Vindesina; Vindesinum; Desacetylvinblastine amide; Lilly 112531; Vindesina [INN-Spanish]; Vindesinum [INN-Latin]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

40839

ChEBI ID

CHEMBL36373

CAS Number

CAS 53643-48-4

TTD Drug ID

D04RLY

VARIDT Drug ID

DR00397

INTEDE Drug ID

DR1693

General Information of Drug (ID: DMVR628)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Peroxisome	-1.58	4.99e-2	72/82 (87.8%)	AGXT;ABCD2;PEX10;...
Primary bile acid biosynthesis	-1.62	4.12e-2	15/17 (88.24%)	BAAT;AKR1C4;ACOT8;...
Thiamine metabolism	-1.63	3.96e-2	12/15 (80%)	ALPG;AK1;NFS1;...
Folate biosynthesis	-1.66	3.12e-2	23/26 (88.46%)	FPGS;ALPG;MOCS2;...
Sulfur relay system	-1.66	3.02e-2	5/8 (62.5%)	MOCS2;NFS1;TST
Glyoxylate and dicarboxylate metabolism	-1.68	2.90e-2	23/30 (76.67%)	GLUL;CS;AMT;...
Lysine degradation	-1.76	1.13e-2	51/63 (80.95%)	ACAT1;BBOX1;ALDH9A1;...
Glycine, serine and threonine metabolism	-1.77	1.16e-2	31/40 (77.5%)	BPGM;AMT;GCAT;...
Ribosome	-1.78	1.12e-2	113/158 (71.52%)	RPS4X;RPS29;RPL4;...
Mismatch repair	-1.79	1.15e-2	22/23 (95.65%)	POLD4;POLD3;RFC4;...
Steroid hormone biosynthesis	-1.79	1.27e-2	43/61 (70.49%)	HSD3B1;CYP1B1;CYP2E1;...
Fatty acid degradation	-1.81	1.06e-2	40/43 (93.02%)	HADHB;ACAT1;ACAA2;...
Citrate cycle (TCA cycle)	-1.87	3.96e-3	30/30 (100%)	FH;ACLY;SUCLG2;...
Valine, leucine and isoleucine degradation	-1.93	0.00e+0	42/48 (87.5%)	ACAD8;HADHB;IVD;...
Diabetic cardiomyopathy	-1.93	0.00e+0	162/203 (79.8%)	TGFBR2;COX4I1;NDUFS8;...
Propanoate metabolism	-1.96	0.00e+0	30/34 (88.24%)	ACAT1;DBT;EHHADH;...
Metabolism of xenobiotics by cytochrome P450	-2.01	0.00e+0	49/77 (63.64%)	HPGDS;ADH7;CYP1B1;...
One carbon pool by folate	-2.02	0.00e+0	15/20 (75%)	AMT;ATIC;MTR;...
Oxidative phosphorylation	-2.16	0.00e+0	93/133 (69.92%)	COX4I1;NDUFS8;LHPP;...
DNA replication	-2.19	0.00e+0	34/36 (94.44%)	PRIM2;POLD4;POLD3;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	4uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H